Popular
- New cancer treatment uses enzymes to boost immune system...August 29, 2018 - 2:18 PM
- Dr. Georgiou Delivers Prestigious Global Distinguished Lecture...September 12, 2017 - 2:26 PM
- Undergraduate Researcher Justin Mirazee wins a Fall Undergraduate...September 28, 2017 - 6:59 PM
- Dr. Everett Stone Named Emerging Inventor of the YearNovember 3, 2017 - 6:09 PM
Recent
- Our Covid Research Featured on NIH Director’s Blo...May 18, 2021 - 4:40 PM
- The Institute a Member of the Nationwide NIH COVID-19 S...October 8, 2020 - 11:25 PM
- Drs. Ippolito and Lavinder featured in the Austin American...September 23, 2020 - 2:17 PM
- Institute Develops Antibody Test for COVID-19 That is Sensitive,...September 13, 2020 - 4:19 PM
Comments
Tags
Undergraduate Researcher Ahlan Qerqez Accepted to UT CHE
/in News /by adminCongratulations to Ahlam Qerqez who has been accepted to the graduate program at UT Austin in the Chemical Engineering Department. Ahlam will join alum Jennifer Maynard’s lab. https://sites.google.com/site/maynardlabatut/Home
Giulia Agnello Graduates and Accepts Position at Anglea Biotechnology, INC
/in News /by adminCongratulations to Giulia Agnello for successfully defending her thesis, “Development of Human Enzymes for Amino Acid Depletion Therapy,” April 2016. Giulia has accepted a Research Scientist position at Aeglea Biotherapeutics, Inc.
Navin Varadarajan Promoted to Associate Professor
/in News /by adminCongratulations to alum Dr. Navin Varadarajan on being promoted to Associate Professor at University of Houston! http://singlecell.chee.uh.edu/
Congratulations!
/in News /by adminLarge-scale Sequence and Structural Comparisons of Human Naive and Antigen-Experienced Antibody Repertoires
/in News /by adminUT-Austin Researchers Focus on Poliovirus and The Human Immune Response
/in News /by adminAnthrax Treatment Engineered by Texas CHE Researchers Gains FDA Approval
/in News /by adminResearchers at The University of Texas at Austin, including Texas ChE’s Dr. George Georgiou and Dr. Jennifer Maynard, successfully culminated years of work when a drug they engineered for the treatment and prevention of inhalational anthrax — the anthrax antitoxin obiltoxaximab — received approval March 21 from the U.S. Food and Drug Administration (FDA). Part of the molecule was engineered at UT Austin before being licensed to New Jersey-based pharmaceutical company Elusys Therapeutics for further development. It will be sold under the name Anthim.
https://che.utexas.edu/2016/04/04/anthrax-treatment-engineered-texas-che-researchers-gains-fda-approval/
Fighting Lymphoma Cancer with Genomics and Supercomputing
/in News /by adminDr. Georgiou Elected to the National Academy of Inventors
/in News /by adminGeorge Georgiou, 2014 UT Austin Inventor of the Year
/in News /by admin